Clinical presentation is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical presentation, imaging inspection, laboratory testing and pathological activation.
A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Individual treatment plans for treatment and management of H. L.
are needed, usually including drug therapy, rehabilitation interventions, and regular follow-up to multiple-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the course of the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of post-chemotherapy HL. The platform serves a team of internationally authoritative experts at home and abroad in the field of blood tumours linked to the China International Medical Service System, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.